HC Wainwright Issues Optimistic Outlook for FHTX Earnings

Foghorn Therapeutics Inc. (NASDAQ:FHTX) – Stock analysts at HC Wainwright raised their Q3 2026 EPS estimates for shares of Foghorn Therapeutics in a report released on Friday, May 8th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($0.28) per share for the quarter, up from their prior forecast of ($0.29). HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($1.03) per share. HC Wainwright also issued estimates for Foghorn Therapeutics’ Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($1.06) EPS, FY2027 earnings at ($0.90) EPS, FY2028 earnings at ($0.57) EPS, FY2029 earnings at ($0.04) EPS and FY2030 earnings at $0.36 EPS.

Several other analysts have also recently commented on FHTX. Wedbush restated an “outperform” rating and issued a $10.00 target price on shares of Foghorn Therapeutics in a research note on Thursday, March 12th. Jefferies Financial Group restated a “buy” rating on shares of Foghorn Therapeutics in a research note on Thursday, March 12th. Wall Street Zen cut shares of Foghorn Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Foghorn Therapeutics in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $11.13.

Foghorn Therapeutics Stock Performance

FHTX stock opened at $4.33 on Tuesday. Foghorn Therapeutics has a one year low of $3.27 and a one year high of $6.95. The stock has a market capitalization of $254.21 million, a PE ratio of -3.73 and a beta of 2.97. The company has a fifty day moving average of $5.02 and a 200-day moving average of $5.06.

Foghorn Therapeutics (NASDAQ:FHTX) last released its earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.01). The firm had revenue of $3.27 million for the quarter, compared to the consensus estimate of $7.94 million.

Hedge Funds Weigh In On Foghorn Therapeutics

A number of large investors have recently made changes to their positions in the stock. Raymond James Financial Inc. increased its holdings in shares of Foghorn Therapeutics by 4.0% in the 3rd quarter. Raymond James Financial Inc. now owns 2,462,488 shares of the company’s stock valued at $12,042,000 after purchasing an additional 95,196 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Foghorn Therapeutics by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 1,899,457 shares of the company’s stock valued at $9,288,000 after purchasing an additional 14,784 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Foghorn Therapeutics by 16.9% in the 2nd quarter. Geode Capital Management LLC now owns 807,674 shares of the company’s stock valued at $3,797,000 after purchasing an additional 116,979 shares in the last quarter. Candriam S.C.A. purchased a new position in shares of Foghorn Therapeutics in the 1st quarter valued at about $1,500,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Foghorn Therapeutics by 151.8% in the 4th quarter. Renaissance Technologies LLC now owns 297,736 shares of the company’s stock valued at $1,608,000 after purchasing an additional 179,500 shares in the last quarter. Hedge funds and other institutional investors own 61.55% of the company’s stock.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel epigenetic therapies for cancer. The company leverages its proprietary Targeted Protein Discovery Platform to identify and design small-molecule inhibitors that modulate chromatin regulatory proteins involved in tumor growth and survival. By targeting the mechanisms that control gene expression, Foghorn seeks to address unmet needs in oncology through precision medicine.

The company’s lead candidate, FHD-286, is a selective inhibitor of variant SWI/SNF chromatin remodeling complexes and is currently being evaluated in Phase 1 clinical trials for patients with solid tumors harboring specific SMARCA2 and SMARCA4 alterations.